MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management: A Paradigm Shift in Detection, Grading, Monitoring, Staging, Reporting, Biopsy and Treatment

Saturday, February 17, 2018
UCLA Meyer & Renee Luskin Conference Center
UCLA Campus
Los Angeles, California
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:
A Paradigm Shift in Detection, Grading, Monitoring, Staging, Reporting, Biopsy and Treatment

General Information:
Saturday, February 17, 2018

Registration Fees:
MD Early bird (by January 28, 2018)  $275
MD (beginning January 29, 2018)  $325
Fellows/Residents/Techs   $200

Program Location:
UCLA Meyer & Renee Luskin Conference Center
425 Westwood Plaza
Los Angeles, CA 90095
855-522-8252
www.luskinconferencecenter.ucla.edu

Refunds:
Cancellations must be received in writing by Friday, February 2, 2018 and will be subject to a $50 processing fee. No refunds will be granted after the cutoff date. If, for any reason, the course must be canceled, discontinued, or rescheduled by the Office of Continuing Medical Education, a full refund will be provided.

Directions and Parking:
From the 405 freeway, exit Wilshire Blvd., East toward Westwood. Turn left on Westwood Blvd., travel past Charles E. Young Dr. South and turn left on Structure 8 driveway. Drive up the ramp to the rooftop level to park. Parking attendants will be selling permits from 6:30 AM - 8:30 AM. If you arrive outside of this time frame, please visit the parking kiosk on Westwood Plaza to pay for your parking permit. Participants are responsible for their own parking charges at a rate of $12 per vehicle. The Luskin conference center is located at Westwood Plaza and Strathmore Place.

Additional Information:
If you have any questions, please contact the UCLA Office of Continuing Medical Education at (310) 794-2620 or visit our website at www.cme.ucla.edu.

Faculty

Course Director
Steven S. Raman, MD, FSAR, FSIR
Professor of Radiology, Urology and Surgery
David Geffen School of Medicine

UCLA Faculty
Corey Arnold, PhD
Assistant Professor of Radiology and Bioengineering
David Geffen School of Medicine

Albert Chang, MD, PhD
Associate Professor and Vice Chair, Surgical Services
Director of Brachytherapy Services
David Geffen School of Medicine

Johannes Czernin, MD
Professor of Molecular Pharmacology
David Geffen School of Medicine

Ely Felker, MD
Assistant Professor of Radiology
David Geffen School of Medicine

William Hsu, PhD
Associate Professor of Radiology
David Geffen School of Medicine

David S. K. Lu, MD
Professor of Radiology and Surgery
David Geffen School of Medicine

Leonard Marks, MD
Professor of Urology
David Geffen School of Medicine

Justin McWilliams, MD
Associate Professor of Radiology
David Geffen School of Medicine

Allan Pantuck, MD
Professor of Urology
David Geffen School of Medicine

Matthew Rettig, MD
Professor of Oncology
David Geffen School of Medicine

Robert Reiter, MD
Professor of Urology
David Geffen School of Medicine

Anthony Sisk, DO
Assistant Professor of Pathology
David Geffen School of Medicine

Guest Faculty
Daniel J. Margolis, MD
Associate Professor of Radiology
Weill Cornell School of Medicine
PROGRAM
Saturday, February 17th

7:00  Breakfast and Registration

8:00  Introduction to Prostate MRI  Steven S. Raman, MD, FSAR, FSIR
8:10  T2/Anatomy  Daniel J. Margolis, MD
8:25  Diffusion Weighted Imaging  Daniel J. Margolis, MD
8:40  Perfusion Imaging  Daniel J. Margolis, MD
8:55  Understanding PIRADS v2  Ely Felker, MD
9:10  Case 1: Active Surveillance and MRI  Steven S. Raman, MD, FSAR, FSIR
9:15  Active Surveillance and MRI  Leonard Marks, MD
9:30  Active Surveillance and Targeted Fusion Biopsy  Leonard Marks, MD
9:45  US Fusion Biopsy Systems: UroNAV and Koelis  Allan Pantuck, MD
10:00  MRI-Guided In-Bore Prostate Biopsy  David S. K. Lu, MD
10:15  Panel Discussion
10:30  Morning Coffee Break
11:00  Case 2: Surgical and Radiation Planning MRI  Steven S. Raman, MD, FSAR, FSIR
11:05  Indications for Prostate MRI  Daniel J. Margolis, MD
11:20  PSMA PET: The Best for Prostate Cancer Dx?  Johannes Czernin, MD
11:35  Surgical Planning with Prostate MRI  Robert Reiter, MD
11:50  Prostate Pathology  Antony Sisk, DO
12:05  Radiation Therapy Planning and MRI  Albert Chang, MD, PhD
12:20  Panel Discussion
12:35  Lunch
1:25  Case 3: Focal Therapy: Hope or Hype?  Ely Felker, MD
1:30  Pros of Focal Therapy  Leonard Marks, MD
1:45  Cons of Focal Therapy  Robert Reiter, MD
2:00  MR Imaging of Focal Therapy  Ely Felker, MD
2:15  Prostate Cryo, HIFU and Laser Ablation  Leonard Marks, MD
2:45  Emerging Ablative Therapies  Steven S. Raman, MD, FSAR, FSIR
3:00  Prostate Artery Embolization  Justin McWilliams, MD
3:15  Panel Discussion
3:30  Afternoon Coffee Break
4:00  Artificial Intelligence and Prostate MRI: The Future  Corey Arnold, PhD
4:15  Utility of Prostate Biomarkers  Robert Reiter, MD
4:30  PI-RADS v2 as an Imaging Biomarker  Daniel J. Margolis, MD
4:45  Radiogenomics and MRI: Imaging and Biology  William Hsu, PhD
5:00  Imaging as a Predictive Biomarker  Robert Reiter, MD
5:15  Understanding Advanced Prostate Cancer  Matthew Rettig, MD
5:45  Panel Discussion
6:00  Adjourn
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management

<table>
<thead>
<tr>
<th>Course Title and Number</th>
<th>Registration Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD Early bird (by January 28, 2018)</td>
<td>$275</td>
</tr>
<tr>
<td>MD (beginning January 29, 2018)</td>
<td>$325</td>
</tr>
<tr>
<td>Fellows/Residents/Techs/Nurses</td>
<td>$200</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
</tr>
</tbody>
</table>
Prostate cancer is the second most common solid organ malignancy diagnosed in men. Unlike other solid organ malignancies, the challenge in prostate cancer is to confidently identify men with moderate and high grade cancers who would benefit most from aggressive therapy and triage the rest to active surveillance. Uniquely among solid organ cancers, imaging has not been a traditional part of the workup for prostate cancer, which has relied instead on transrectal US-guided template biopsy. Over the past few years, MR imaging has emerged as the best imaging modality to detect, grade and stage prostate cancer and is considered a valuable biomarker. The course will focus on the evolving role of MR imaging in prostate cancer diagnosis, monitoring, targeted biopsy and in focal and whole gland therapy planning. We will review all relevant MR imaging components of prostate cancer, new molecular modalities such as PSMA PET and an update on prostate cancer biomarkers.

Target Audience:
Radiologists, urologists, radiation and medical oncologists and primary care physicians interested in understanding prostate MR imaging and its applications for active surveillance, biopsy planning and acquisition, surgical planning and radiation planning and its role as a prostate biomarker

Course Objectives:
At the conclusion of this course, participants should be better able to:

- Understand state-of-the art prostate MR imaging, biomarkers and artificial intelligence
- Integrate prostate MR imaging into active surveillance and targeted biopsy planning
- Incorporate prostate MR imaging into robotic prostatectomy and radiation planning
- Illustrate the role for molecular imaging of prostate cancer: PSMA, Axumin and Choline PET
- Evaluate the risks and benefits of focal and whole gland therapies

Accreditation:
The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Approved by the ASRT for Category A continuing education credit.

Disclosure Statement:
The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the sponsor adequately manage all potential conflicts of interest prior to the program. We, at UCLA, fully endorse the letter and spirit of these concepts.
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:
A Paradigm Shift in Detection, Grading, Monitoring, Staging, Reporting, Biopsy and Treatment

Saturday, February 17, 2018
www.cme.ucla.edu/courses